<DOC>
	<DOCNO>NCT01257568</DOCNO>
	<brief_summary>This study evaluation Rejuvenate® Modular Hip System primary total hip replacement ( THR ) cementless application consecutive series patient meet eligibility criterion . Subjects evaluate freedom hip revision 5 year clinical outcomes 10 year surgery .</brief_summary>
	<brief_title>Rejuvenate Modular Outcomes Study</brief_title>
	<detailed_description />
	<criteria>Patient sign IRB approve , study specific Informed Patient Consent Form . Patient male nonpregnant female age 18 year old time study device implantation . Patient primary diagnosis NonInflammatory Degenerative Joint Disease ( NIDJD ) . Patient candidate primary cementless total hip replacement . Patient willing able comply postoperative schedule clinical radiographic evaluation rehabilitation . Patient 's operative femur template Rejuvenate® Modular Stem size 712 . Patient Body Mass Index ( BMI ) ≥ 40 . Patient active suspect latent infection affect hip joint time study device implantation . Patient neuromuscular neurosensory deficiency , limit ability evaluate safety efficacy device . Patient diagnose systemic disease ( e.g . Lupus Erythematosus ) metabolic disorder ( e.g . Paget 's Disease ) lead progressive bone deterioration . Patient immunologically suppress receive steroid excess normal physiological requirement ( e.g . &gt; 30 day ) . Patient require revision surgery previously implant total hip replacement hip fusion affect joint . Patient known sensitivity device material . Patient prisoner .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>